Recommendation of the President – Tecentriq (atezolizumab)
On 17 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 198/2025 on the reimbursement of the medicinal product Tecentriq (atezolizumab) under the B.6 drug program “Treatment of patients with lung cancer (ICD-10 C34) and pleural mesothelioma (ICD-10 C45)”